About: Stéphane de Botton

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Stéphane de Botton Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) वैज्ञानिक (hi) باحت (ary) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy)
rdfs:label	Stéphane de Botton (en) Stéphane de Botton (es) Stéphane de Botton (nl) Stéphane de Botton (ast)
skos:prefLabel	Stéphane de Botton (en) Stéphane de Botton (es) Stéphane de Botton (nl) Stéphane de Botton (ast)
name	Stéphane de Botton (en) Stéphane de Botton (es) Stéphane de Botton (nl) Stéphane de Botton (ast)
given name	wds:Q57031523-34A4C42A-7019-4107-B063-36C2A2D35702
given name	Stéphane
instance of	wds:Q57031523-88EE2E31-6C4A-4533-BA5D-AFF002C88D9E
instance of	Homo sapiens
doctoral advisor	wds:Q57031523-BD364667-A89B-4868-BD9D-A22529390D49
doctoral advisor	Claude Preudhomme
occupation	wds:Q57031523-616E33E1-EE60-4326-8E84-68C2A518C5F4
sex or gender	wds:Q57031523-a088c5df-0226-4069-be08-eb5a94501280
ISNI	wds:Q57031523-FEE38531-40C2-4657-8653-CBB2022F5BF1
VIAF ID	wds:Q57031523-19AE0364-4FC6-4D50-8329-7F283BB1E25C
IdRef ID	wds:Q57031523-C5E8C25A-2CD1-4F2A-B25C-D115B6B2CDF5
date of birth	wds:Q57031523-62769538-0E08-48F4-AEF1-7A93C9CC6D76
VIAF ID	http://viaf.org/viaf/198872300
IdRef ID	http://www.idref.fr/117547123/id
occupation	researcher
sex or gender	male
ISNI	0000000140848602
VIAF ID	198872300
IdRef ID	117547123
date of birth	1967-01-01 00:00:00Z (xsd:dateTime)
ORCID iD	wds:Q57031523-6EEDAE5A-7E07-4CC5-8ED3-B08C72B58D99
ORCID iD	https://orcid.org/0000-0002-8126-4942
ORCID iD	0000-0002-8126-4942
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57031523
is author of	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients Successful Outcome of DisseminatedFusariumInfection with Skin Localization Treated with Voriconazole and Amphotericin B-Lipid Complex in a Patient with Acute Leukemia Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Platelet formation is the consequence of caspase activation within megakaryocytes Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials Ecto-calreticulin in immunogenic chemotherapy Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group Erlotinib antagonizes ABC transporters in acute myeloid leukemia An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group Treatment of older adults with acute promyelocytic leukaemia Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software